OPINION ARTICLE

The TOUCH program and natalizumab: Fundamental flaw in patient protection [version 1; referees: 2 approved with reservations]

Jagannadha Avasarala
Department of Medicine/Division of Neurology, Greenville Memorial Hospital & Neuroscience Associates, Greenville, SC, 29615, USA

Abstract
Many drugs have been approved by the Food and Drug Administration (FDA) since 1993 for treatment of relapsing forms of multiple sclerosis (MS). One such drug is natalizumab (Tysabri, Biogen Idec and Elan pharmaceuticals) which has enjoyed great success in the management of MS since its re-introduction in 2006. One of the complications of using natalizumab is the risk of development of progressive multifocal leukoencephalopathy (PML). To mitigate the risk of PML development, Biogen Idec initiated the TOUCH program – this strategy helps monitor the disease. Clinical vigilance is remains key in the early diagnosis of PML but serological testing for the John Cunningham Virus Antibody (JCV) helps with risk stratification of PML. However, some physicians do not test for the JCV Ab and since they are not required to send such data to the company or inform the patient, one red flag for suspicion of PML is lost particularly if the patient is asymptomatic. This undercuts the premise of the TOUCH program. In an ideal world, reporting JCV Ab status should be made mandatory since that ensures a basic tenet of the program is met – to identify patients at increased risk of developing PML and make appropriate recommendations based on that finding. Lack of requirement of reporting of this vital finding opens the door for uncertainty in assessment of risk PML development and everyone remains in the dark till it may be too late. This is unacceptable when the company created the TOUCH program specifically with intent to track PML risk in patients on natalizumab. It makes no scientific sense to let the drug be used without setting stringent criteria given the possibility of PML development.
Natalizumab is the first monoclonal antibody approved for the treatment of relapsing forms of multiple sclerosis (MS) and is used in more than 50 countries. Natalizumab is a recombinant humanized monoclonal IgG4 antibody that binds to alpha 4 beta 1 integrin and interferes with alpha 4-mediated binding to extracellular matrix and endothelial lining, vascular cell adhesion molecule (VCAM1) and fibronectin. After its initial approval in 2004 by the FDA, it was voluntarily withdrawn in early 2005 after two patients with MS in the SENTINEL trial and 1 patient with Crohn’s disease were diagnosed with progressive multifocal leukoencephalopathy (PML).1-3

The drug was reapproved in 2006 and recommendations were made in the US to limit its use to highly active relapsing-remitting MS (with more than two relapses per year) and to those patients who did not respond or tolerate first-line treatment such as interferon beta-1a, interferon beta-1b, or glatiramer acetate. As well, a restricted risk minimization plan was also initiated to better assess an individual’s risk of PML: Tysabri Outreach: Unified Commitment to Health [TOUCH]. This created a system where only prescribers and patients enrolled in the TOUCH program could prescribe and receive the drug. Additionally, only certain pharmacies and infusion sites authorized by the TOUCH prescribing program could dispense and infuse natalizumab. The primary goals of the program were to inform prescribers, infusion center healthcare providers and particularly patients, about the risk of development of PML associated with natalizumab use including the positive association of increased risk of PML and a) treatment duration, b) prior immunosuppressant use and c) JCV Ab status. The TOUCH program also includes information on and warnings against concurrent use of natalizumab with antineoplastic, immunosuppressant, or immunomodulating agents and in patients who are immunocompromised. The TOUCH program is solely designed to facilitate PML risk assessment at the individual patient level and promote early diagnosis and timely discontinuation of natalizumab in the event of suspected PML.

However, the way the TOUCH program is applied in the real world is less than desirable. For instance, the FDA has not approved the validity or applicability of the JCV Ab index (anti-JCV Ab levels in serum/plasma) which may differentiate PML associated with natalizumab use from other conditions. Despite its lack of FDA approval status, the JCV Ab index is widely used by MS clinicians in the risk evaluation of PML development. Clinicians worry once the index begins to rise although doubling the index value does not automatically confer twice the risk of PML development. Since the index is not FDA-approved, the TOUCH program cannot mandate its use but every patient who has some basic understanding of the PML saga in MS wants to know his/her JCV Ab index. Laboratories run the test, clinicians use it for better or worse and yet the TOUCH program cannot adopt it. It is not an inherent flaw of the TOUCH program itself but sooner rather than later, the FDA should establish whether the JCV Ab index is valid and whether it can be part of a modified TOUCH program or not.

Another confusing test that some clinicians continue to use without rhyme or reason and on a monthly basis is the measurement of JCV DNA viremia.1 This too, akin to the JCV Ab index, is not part of the TOUCH program risk assessment strategy for PML. Although viremia by itself is not a predictor of PML risk, that it can occur in JCA Ab negative patients ‘raises other issues’ according to authors who advocate ‘periodic monitoring’ over the course of the treatment with natalizumab without offering specific time-specific testing protocols.1 Again, the TOUCH program administrators cannot be responsible if testing for JCV viremia does not have scientific relevance and if uninformed clinicians continue to pursue JCV DNA studies religiously, falsely assuming that they are tracking PML – they are not. The test is superfluous and literally a waste of patient’s blood and money.

The biggest fundamental flaw in the TOUCH program is Biogen’s reauthorization questionnaire wherein physicians are allowed to prescribe natalizumab despite the fact that JCV Ab status is not tested or necessarily even reported. Therefore, a clinician can order natalizumab to be administered to patients without periodically reporting (every 6 months) the patient’s JCV Ab status to the company as this is not mandatory and without it, patients can still stay in the TOUCH program. Most clinicians do track PML using JCV Ab status every 6 months as required but as a neurologist and a fellowship-trained multiple sclerosis physician, I have seen patients without JCV Ab testing or reporting who yet continue to be in the TOUCH program. It is also true that JCV Ab status, if positive, does not imply PML development, but it begs the question as to why the TOUCH program does not insist that JCV Ab status be reported every 6 months. A simple solution would be to make the JCV Ab status available to the company and if the patient and their physician decide to continue the drug despite JCV Ab status being positive, that is a choice between the patient and physician. Obviously, JCV Ab positive status is one of many factors that can increase the risk of PML development – use of the drug beyond two years and prior immunosuppressant use also increase the risk of PML. Clinicians understand and agree that early diagnosis of PML hinges on clinical vigilance.

Since Biogen Idec and the FDA are interested in halting PML in its tracks, and there have been, as of September 4, 2015, a total of 588 confirmed cases of PML while on natalizumab,6 it must be obvious for all those concerned with patient safety that it is necessary to plug this loophole. Strangely enough, confirmed PML cases from natalizumab use are not available in a database for researchers to probe into individual (personal details can be encrypted) cases for analysis. The primary goal of the TOUCH program is to address risk stratification of PML and therefore, allowing clinicians to continue to prescribe natalizumab without knowledge of the JCV Ab status is a huge risk. It would be an easy recommendation to make JCV Ab testing mandatory; making JCV Ab status reporting the sine qua non for prescribing this drug adds one more layer of protection to patients.
It is unknown if any of the 588 reported cases of PML fall into the category that I have described – even if only one patient did, this would call into question whether it was preventable and what the role of the TOUCH program should be in preventing it. One wonders what proportion of patients do not have their JCV Ab status reported across the globe while in the TOUCH program. Since hundreds of PML cases are already known, and more will likely continue to be reported, it is conceivable that questions will be raised as to whether more could have been done to prevent such cases. I hope there are no instances of PML owing to omission of JCV Ab status evaluation but I also think it is time for FDA to act now to prevent future lapses and avoid legal nightmares. My suggestion would be to make reporting of JCV Ab status mandatory for all patients on natalizumab in the TOUCH program - from a pharmacovigilance perspective, this makes perfect sense.

Competing interests
No competing interests were disclosed.

Grant information
The author(s) declared that no grants were involved in supporting this work.

References

6. Quarterly safety update, Biogen Idec.
Open Peer Review

Current Referee Status: ?  ?

Version 1

Referee Report 09 February 2016

doi:10.5256/f1000research.8092.r12282

Nicholas Schwab
Department of Neurology, University Hospital Münster, Münster, Germany

The first point I would like to make (as it is mentioned in the abstract) is that TOUCH has not been introduced by Biogen as a method to mitigate PML risk, but as a method to inform patients and physicians of the PML risk and to monitor the patients for early signs of PML allowing for a better diagnosis and treatment. While some might argue that PML prevention should be the ultimate goal of TOUCH, it has not been designed to do that and one can hardly blame the program for not reaching a goal it has not been set up to achieve.

The FDA approval of the JCV index should indeed be pursued, as the author is right in assuming that patients and physicians already use the JCV index in risk stratification decisions and the sooner the FDA rules on the biomarker, the better, so it can be applied during TOUCH in a coordinated and sensible way.

The data concerning JCV viremia and PML risk does not support it as a risk biomarker and I would either downright state that or remove the paragraph.

I agree with the author that the consequent monitoring and application of the JCV serology would be a step towards reducing PML incidence, as JCV serology is still the most sensitive biomarker with regard to PML development. However, I would personally say that it is up to patient and physician to either use the serology or choose not to. While the goal of maximum safety is a commendable one, I would argue that personal choice on whether a patient wants to know their JCV status is even more important. It would be a different situation, if the JCV serology had a high specificity, then the use of natalizumab should be restricted to anti-JCV negative patients. With a low specificity of ca. 45% it can be reasoned that a patient does not want to know their status, if they urgently need to use natalizumab anyway and prefer not to be worried about their PML risk.

While it would be a great data resource to know and monitor the JCV serostatus (and potentially index) of all TOUCH patients, to force a biomarker with low specificity on patients, who might choose not to use it, would have far-reaching consequences. The knowledge of their JCV serostatus has not prevented the occurrence of the 300+ PML, where it was available before, so I do not think that the mandatory use would help in this regard. The biomarker should, however, be available to all patients, who want to use it, so no PML cases develop, where the patient was unaware of their possibility to test for anti-JCV antibodies. To my knowledge, this is already the case. The TOUCH program should be updated in the future to include possible alternative biomarkers as well and serve as a monitoring platform.

Having said that, I fully support the author’s with for a usable database, where physicians and researcher
I fully support the author's wish for a usable database, where physicians and researchers can access the data of the PML patients for research purposes to get a better handle on this devastating disease.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Competing Interests:** I have received travel funding from Biogen, speaker honoraria from Novartis, and hold a patent for usage of L-selectin as a predictive marker for PML.

---

**Author Response 09 Feb 2016**

**Jagannadha Avasarala**, Greenville Hospital System University Medical Center, USA

I thank Dr Schwab for his insight and comments on my article. Here are my responses, itemized.

1. To quote the TOUCH program official website statement *verbatim*, under the sub-heading of ‘a commitment to patient safety’, the following is noted -
   - Because of the risk of PML, TYSABRI® (natalizumab) is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH® Prescribing Program.

2. One has to also note that REMS, an FDA mandated program, noted the following for TYSABRI use - To inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the a) increased risk of PML with longer treatment duration, b) prior immunosuppressant use and c) the presence of anti-JCV antibodies.

The above mentioned strategies came to a head with the development of STRATIFY, a test developed to stratify PML risk, and approved by the FDA in 2012 to monitor PML risk. As well, Biogen has a questionnaire that all healthcare providers enrolled in the TOUCH program have to complete every 6 months *that includes a section regarding the JCV Ab status*. My question is simple - what is the point of the TOUCH program, STRATIFY test, FDA approval of risk mitigation strategies, inclusion of the JCV Ab status in the questionnaire, etc., if physicians are allowed to discard the very test that is supposed to protect a patient by stratification of risk guidelines? Clinical surveillance, frequent MRI evaluations, history of use of other immuno-suppressant drugs in the past, as well as duration are all factors that drive PML risk higher but what of the company that put all the pieces of risk evaluation in the first place? One cannot walk away from the basic tenet in this discussion with semantics - patient protection from PML in TYSABRI users. From 2012 and beyond, after the STRATIFY was developed, there is no excuse for Biogen to let physicians prescribe TYSABRI without checking for JCV Ab status and certainly one way of reassuring the medical community would be to a) make testing mandatory for TYSABRI continuation and b) make the PML database open to researchers to investigate if cases were indeed missed as a result of this simple error.

Jagannadha Avasarala

**Competing Interests:** None
David B Clifford
Department of Neurology, Washington University in St. Louis, St Louis, MO, USA

I think that advocating to legislate science that is admittedly not yet accepted as useful is not such a good idea. Changing the goal to driving data collection to decide risk stratification that avoids PML might be a good idea. TOUCH was not created to provide risk stratification, but to help assure early diagnosis. If there is any enhancement, it might be better to advocate for frequent MRI which do appear to improve outcomes for PML. To date, there is no prospective evidence that antibody monitoring prevents PML, and indeed if anything the evidence is that it does not, since cases continue while it is available. I would suggest re-working the recommendation to a program that helps prove if antibody data actually can help physicians prevent PML.

I recommended removing the distracting paragraph about JC DNA.

I would recommend including frequency of imaging as part of TOUCH since it appears to help make earlier diagnosis and improve outcomes.

I think questioning whether TOUCH is effective at present is realistic.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Competing Interests: I have consulted for Biogen regarding PML, as well as several other companies including Takeda, BMS, Genzyme, Pfizer, Amgen, Genentech, GSK, Merck/Sorono, Astra Zeneca, and Inhibikase.

Jagannadha Avasarala, Greenville Hospital System University Medical Center, USA

I thank Dr Clifford for his erudite observations.

1. I agree that the TOUCH program helps in early diagnosis - in fact, the following are explicitly stated on the touchprogram.com, thus:

   - Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use.
   - Warn against concurrent use with antineoplastic, immunosuppressant, or immunomodulating agents and in patients who are immunocompromised.
   - **Promote early diagnosis of PML** and timely discontinuation of TYSABRI in the event of suspected
   - Furthermore, in the important safety information section, it is clearly noted that risk factors for the development of PML include duration of therapy, prior use of immunosuppressants, and presence of anti-JCV antibodies.
As clinicians, we all know that ‘early diagnosis’ of PML includes the STRATIFY testing protocol approved by the FDA in 2012 and that test is designed specifically to assess PML risk. We also understand and know that JCV Ab negative status also carries risk of PML development but what we cannot ignore what the safety information (noted above) and STRATIFY testing are designed to do. Therefore, uncoupling the TOUCH program from testing/reporting JCV Ab status is not only dangerous and fallacious, it runs counter to the argument that there is any ‘risk stratification’ being done if this simple testing is forgotten or discarded.

No one can claim that JCV Ab monitoring prevents PML and nor do I state that; but assessing PML risk with STRATIFY is a fundamental principle of the test or we could discard the test altogether! That frequent MRI testing, clinical surveillance (most critical) and patient self-reporting of new symptoms or worsening of existing symptoms is paramount to the diagnosis of PML is a well established fact, based on scientific evidence.

If JCV Ab testing is of such low importance, why does the TOUCH program questionnaire include this as part of their questionnaire? One cannot have it both ways. Either the testing is critical or we do not test it at all and shun the JCV Ab testing as well as the JCV index. Why have a test approved by the FDA (Stratify), create the TOUCH program to monitor and track PML, include JCV Ab status in the questionnaire that is generated by the company and yet reject the very idea of monitoring for PML by throwing away the JCV Ab testing?

The statement that "TOUCH program was created to help assure early diagnosis" utterly does not hold water if JCV Ab testing is not done. As pointed out in my paper, the questionnaire itself includes it! What is the inclusion for? It is not exactly for statistical purposes, is it?

Dr Avasarala, MD, PhD

Competing Interests: None

Author Response 03 Feb 2016

Jagannadha Avasarala, Greenville Hospital System University Medical Center, USA

I would also submit the following, additional comments.

The TOUCH program, when it was first introduced, did not have the benefit of STRATIFY, approved in 2012. But once JCV Ab testing was FDA approved in 2012, and JCV Ab status testing was part of the TOUCH questionnaire to continue Tysabri use, it became an essential tool to monitor PML risk (in fact, the word Stratify is itself a connotation to categorize risk of PML) so how it is part of a strategy to assess PML risk and yet can be ignored at the same time does not add up. If patients are to be protected or their risk explained to them, every single tool available needs to be put to use. Simple as that.

Competing Interests: None.